GammaCan International Inc

GammaCan International, Inc. (GammaCan) is a life science company engaged in developing proprietary immunotherapies for the treatment of melanoma and other cancers. Its patented platform technology is based on the use of IgGs (Intravenous immunoglobulins), a relatively non-toxic human plasma-derived product used to treat various immune deficiencies and autoimmune diseases. In 2007, GammaCan entered into an agreement with DCI Management Group, LLC. for the purchase and sale of blood plasma. The company carries out its operations in Israel and the United states. It is headquartered in Kiryat Ono, Israel.The operating loss of the company was USD 5.18 million during the fiscal year 2007, as compared to an operating loss of USD 2.04 million during 2006. The net loss of the company was USD 5.18 million during the fiscal year 2007, as compared to a net loss of USD 2.06 million during 2006.